Taconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone Metastasis
(Thomson Reuters ONE) -
Researchers hopeful this new model will address incurable and painful disease
HUDSON, N.Y., July 05, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global
leader in genetically engineered mouse models and associated services, announced
it has signed a collaborative agreement with Pharmatest Services, Ltd.
("Pharmatest") to leverage the company's oncology and skeletal disease
preclinical efficacy services using Taconic's humanized mouse models.
Bone metastasis develops when cancer spreads from elsewhere in the body and is a
frequent downstream consequence of common cancers, such as breast, prostate, and
lung cancer(1,2). Human Immune System (HIS) engrafted models are a key research
tool for studying immune system effects on disease states and are rapidly
becoming the preferred method for testing the efficacy of immune-cell-activating
oncology therapeutics. Without a consistent model of responsive human immune
cells, it has been difficult to assess human-specific, immune-activating
therapies. Taconic's collaboration with Pharmatest brings to the commercial
market the first HIS model used for studying bone metastasis.
"Despite its high frequency in breast, prostate, and lung cancer patients, bone
metastasis is typically considered to be incurable and therapeutic development
for this painful disease has been stymied by the lack of relevant animal models
for studying efficacy of immunotherapies. Taconic is excited to partner with
Pharmatest to address this large unmet need," shared Dr. Azusa Tanaka, product
manager for Taconic's precision research model portfolio.
Pharmatest developed this animal model to clarify the role of human immune cells
in bone metastases using Taconic's huNOG model. This model has both human cancer
and immune cells in the bone, enabling study of a wide variety of cancer drugs
on bone metastasis, including immuno-oncology drugs like checkpoint inhibitors
PD-1, PDL-1, and CTLA-4. It is also valuable when human T cells are required
for the cancer drug to be efficacious. The model is available via Pharmatest.
"Working with Taconic has been a great pleasure for Pharmatest. We are impressed
with the high quality services, top-level scientific support, and fast and clear
communication. By using humanized mice provided by Taconic, we have been able to
establish more predictive animal models to support immuno-oncology therapy
development," stated Dr. Jenni Bernoulli, chief operating officer at Pharmatest.
Taconic offers a full suite of immunology products and services, including germ-
free animal models and microbiome services, a portfolio of humanized models
based on the severely immune-deficient CIEA NOG mouse®, key inbred strains such
as B6, BALB/c, C3H and DBA/1, models on the B6 or BALB/c background which are
lacking particular immune cell types or which carry markers such as OT-II, the
broadest range of immunodeficient strains for use as xenograft hosts, and a full
suite of genomic engineering technologies.
Pharmatest is a preclinical contract research organization that offers high
quality efficacy services in oncology and skeletal diseases, such as
osteoporosis and osteoarthritis. As bone specialists, Pharmatest also offers
bone safety studies and in oncology, Pharmatest has special expertise in
clinically predictive orthotopic and metastasis models, and has been the leading
global provider of bone metastasis models since 2007. Information can we
requested via info(at)pharmatest.com.
1. https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-
cancer/what-is.html
2. http://www.mcancer.org/bone-metastasis
To learn more about Taconic's immune-oncology models and services, please call
1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or
email info(at)taconic.com.
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered
rodent models and services. Founded in 1952, Taconic helps biotechnology
companies and institutions acquire, custom generate, breed, precondition, test,
and distribute valuable research models worldwide. Specialists in genetically
engineered mouse and rat models, precision research mouse models, and integrated
model design and breeding services, Taconic operates three service laboratories
and six breeding facilities in the U.S. and Europe, maintains distributor
relationships in Asia and has global shipping capabilities to provide animal
models almost anywhere in the world.
Media Contact:
Kelly Owen Grover
Director of Marketing Communications
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.07.2017 - 23:26 Uhr
Sprache: Deutsch
News-ID 551214
Anzahl Zeichen: 5444
contact information:
Town:
Hudson
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Taconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone Metastasis"
steht unter der journalistisch-redaktionellen Verantwortung von
Taconic Biosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
